List of Excipients in Branded Drug MOMETASONE FUROATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	MOMETASONE FUROATE MONOHYDRATE	mometasone furoate monohydrate	0781-6355	BENZALKONIUM CHLORIDE
Sandoz Inc	MOMETASONE FUROATE MONOHYDRATE	mometasone furoate monohydrate	0781-6355	CARBOXYMETHYLCELLULOSE SODIUM
Sandoz Inc	MOMETASONE FUROATE MONOHYDRATE	mometasone furoate monohydrate	0781-6355	CELLULOSE, MICROCRYSTALLINE
Sandoz Inc	MOMETASONE FUROATE MONOHYDRATE	mometasone furoate monohydrate	0781-6355	CITRIC ACID MONOHYDRATE
Sandoz Inc	MOMETASONE FUROATE MONOHYDRATE	mometasone furoate monohydrate	0781-6355	GLYCERIN
Sandoz Inc	MOMETASONE FUROATE MONOHYDRATE	mometasone furoate monohydrate	0781-6355	POLYSORBATE 80

Generic Drugs Containing MOMETASONE FUROATE

Company	Ingredient	NDC	Excipient
E Fougera & Co a division of Fougera Pharmaceuticals Inc	mometasone furoate	0168-0270	ALUMINUM STARCH OCTENYLSUCCINATE
E Fougera & Co a division of Fougera Pharmaceuticals Inc	mometasone furoate	0168-0270	HEXYLENE GLYCOL
E Fougera & Co a division of Fougera Pharmaceuticals Inc	mometasone furoate	0168-0270	PETROLATUM
E Fougera & Co a division of Fougera Pharmaceuticals Inc	mometasone furoate	0168-0270	PHOSPHORIC ACID
E Fougera & Co a division of Fougera Pharmaceuticals Inc	mometasone furoate	0168-0270	POLYOXYL 20 CETOSTEARYL ETHER
E Fougera & Co a division of Fougera Pharmaceuticals Inc	mometasone furoate	0168-0270	PROPYLENE GLYCOL MONOPALMITOSTEARATE

What are the Most Frequently-Used Excipients in MOMETASONE FUROATE?

# Of NDCs	Excipient
25	ALUMINUM STARCH OCTENYLSUCCINATE
5	BENZALKONIUM CHLORIDE
5	CARBOXYMETHYLCELLULOSE SODIUM
5	CELLULOSE, MICROCRYSTALLINE
1	CETEARETH-20
5	CITRIC ACID MONOHYDRATE

Excipient Strategy and Commercial Opportunities for Mometasone Furoate

Last updated: March 3, 2026

A strategic excipient framework enhances product stability, bioavailability, and patient compliance for mometasone furoate. Maximizing excipient utility improves commercial prospects and regulatory compliance.

What Are Key Excipient Functions in Mometasone Furoate Formulations?

Mometasone furoate (MF) is a topical corticosteroid used in nasal sprays, creams, and inhalers. Excipient roles typically include:

• Preservatives: Prevent microbial growth (e.g., benzalkonium chloride).
• Stabilizers: Maintain chemical integrity, especially in aqueous formulations.
• Penetration enhancers: Facilitate dermal or mucosal absorption (e.g., ethanol, propylene glycol).
• Viscosity modifiers: Improve application and retention (e.g., carbomers, hypromellose).
• pH adjusters: Optimize drug stability and tolerability (e.g., citric acid).
• Carriers/Diluents: Enable appropriate drug dispersal (e.g., aero-grade talc).

Excipient Selection Based on Formulation Type

Formulation Type	Common Excipients	Key Functional Concerns
Nasal spray	Benzalkonium chloride, Citrates, Glycerin	Microbial stability, isotonicity, and tolerability
Topical cream	Glyceryl stearate, Carbomers, Propylene glycol	Emulsion stability, skin penetration
Inhaler	Propellants, Surfactants, Stabilizers	Dispersibility, particle size control

Strategic Excipient Innovations in Mometasone Furoate Development

Emerging trends emphasize compatibility with sensitive drug molecules, patient-friendly formulations, and regulatory compliance:

1. Biocompatibility: Opt for excipients with established safety profiles. For example, replacing benzalkonium chloride with phenoxyethanol reduces irritation.
2. Reduced Preservative Use: Single-dose formulations eliminate preservatives, decreasing side effects and regulatory hurdles.
3. Enhanced Penetration: Incorporate novel permeation enhancers such as permeation peptides or nanocarrier systems to improve efficacy.
4. Stability Improvements: Use antioxidants like tocopherols to prevent oxidation of MF, extending shelf life.
5. Functionalization: Develop excipients that improve mucoadhesion or targeted delivery, such as chitosan derivatives.

Market and Commercial Opportunities

The global corticosteroid market is valued at approximately $10 billion, with mometasone furoate occupying a substantial share in nasal and dermatological segments (QY Research, 2022). Excipient innovation offers differentiation, which can lead to:

Opportunities in Formulation Innovation

• Preservative-Free Nasal Sprays: Addressing concerns over preservative-related irritation attracts sensitive patient groups.
• Enhanced Bioavailability: Nanocarrier formulations can lower dosage, reduce side effects, and improve compliance.
• Combination Products: Incorporate mometasone with other therapeutics (e.g., antihistamines) in optimized excipient matrices.

Regulatory Trends

Regulators increasingly favor excipients with well-documented safety profiles. Incorporating excipients with optional functional benefits, such as bioavailability enhancement or irritation reduction, aligns with regulatory pathways.

Patent Landscape

Patent protections for unique excipient interactions or formulations can extend market exclusivity. Companies investing in excipient innovations might secure patents covering:

• Novel penetration enhancers
• Preservative-free delivery systems
• Multi-compartment containers enabling combination therapies

Market Entry Strategies

• Leverage existing excipient platforms with proven safety profiles to accelerate regulatory approval.
• Target niche markets requiring preservative-free or reduced-irritation products.
• Partner with excipient manufacturers to co-develop formulations with differentiated performance.

Challenges and Risks

• Regulatory restrictions on certain excipients, especially preservatives, limit options.
• Patient variability in response to excipients calls for personalized approaches.
• Manufacturing complexity increases with innovative excipients, raising costs.

Summary Table: Key Excipient Strategies for MF

Strategy	Benefits	Risks
Use of biocompatible preservatives	Safety, regulatory compliance	Limited preservative options
Incorporation of permeation enhancers	Improved efficacy	Potential irritation or toxicity
Formulation with novel mucoadhesives	Increased retention at target site	Regulatory uncertainty
Development of preservative-free systems	Reduced irritation	Manufacturing challenges

Key Takeaways

• Excipient choice in mometasone furoate formulations impacts stability, efficacy, and patient tolerability.
• Innovation focuses on safety, reduced irritation, and enhanced drug delivery.
• Commercial opportunities exist in preservative-free, bioavailability-boosting, and combination products.
• Navigating regulatory pathways requires alignment with safety profiles and patent strategies.

FAQs

1. Which excipients are most common in mometasone furoate nasal sprays?
Benzalkonium chloride (preservative), glycerin (humectant), citrate buffers (pH adjusters).

2. How can excipient choice impact regulatory approval?
Using excipients with extensive safety data simplifies approval and reduces delays.

3. Are preservative-free formulations viable for mometasone furoate?
Yes, single-dose units eliminate preservatives. However, manufacturing complexity and cost increase.

4. What novel excipients could improve mometasone furoate formulations?
Permeation enhancers like chitosan derivatives and mucoadhesive polymers.

5. What market segments benefit most from excipient innovations?
Patients with sensitivities, those requiring high compliance, and markets favoring reduced side effects.

---

References

[1] QY Research. (2022). Global corticosteroid market report.
[2] U.S. Food and Drug Administration. (2021). Guidance for Industry: Preservatives and antimicrobial effectiveness testing.